other

Updated:

Edge BioSystems

A CALIBRE SCIENTIFIC COMPANY | EdgeBio has a team of experienced research professionals that are knowledgeable in next generation sequencing technologies and...

Edge BioSystems

A CALIBRE SCIENTIFIC COMPANY | EdgeBio has a team of experienced research professionals that are knowledgeable in next generation sequencing technologies and applications. From library preparation through data analysis, EdgeBio representatives are there to discuss your project on a custom basis to ensure that you receive the results you need for your research.

General information

Firm type

other

Location

Region

North America

Country

United States

City

Gaithersburg

Corporate office

Gaithersburg, MD, United States

Sector focus

Healthcare ServicesAgriTech & FoodTech

Frequently asked questions

Who runs investment decisions at Edge BioSystems?

The principals or investment decision-makers at Edge BioSystems are not publicly disclosed. The firm does not list a management team or board on its website or in public records. Allocators seeking this information should contact the firm directly.

What sectors does Edge BioSystems focus on?

Based on its name, location, and implied domain, Edge BioSystems focuses on the healthcare services and agricultural technology sectors. The company develops biological systems, which may include diagnostics, therapeutics, or crop-science applications.

How is Edge BioSystems structured?

The firm's organizational structure is not publicly documented. It may operate as a private company backed by a family office or a venture-stage entity. No information is available on whether it uses fund vehicles, direct investments, or other structures.

Where does the underlying wealth for Edge BioSystems come from?

The source of wealth behind Edge BioSystems is not publicly disclosed. The firm does not reveal its ownership or backers in available sources.

What is Edge BioSystems' known posture on co-investments?

There is no public information about Edge BioSystems' involvement in co-investments or partnerships with external investors. The firm does not disclose its investment strategy or deal structures.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on investors?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Gaithersburg other profiles